MEXATALIN
Syrup

Respiratory tract drugs

  • Chemical Composition

    Terbutaline sulphate1,5mg /5 ml

  • Packing

    100ml/Glass Bottle

  • Medical Id

    SY-24

  • License Number

    56/2016

  • License date

    9/3/2016

Excipients Flavour (Raspberry) ,Disodium edetate ,Citric acid , Ethanol , Sodium benzoate , Glycerol , Sorbitol , Sodium hydroxide , Purified water .
Mechanism Of Action Terbutaline, which belongs to beta-agonists group, is a bronchodilator because it dilates (widens) the airways. It works by opening up the air passages in lungs so that air can flow into lungs more freely.
INDICATIONS MEXATALIN is indicated for the treatment of breathing disorders, such as bronchial asthma, chronic bronchitis, and emphysema. It helps to relieve tightening of the chest and difficulty breathing (bronchospasm).
CONTRAINDICATIONS Hypersensitivity to the sympathomimetic amines or any other components of the product.
Side EFFECTS The most common side effects include shakiness (tremors), headaches, heart palpitations (feelings of a rapidly or forcefully beating heart). The other side effects include allergic reactions (face edema, urticaria, respiratory disorder, and hypotension), nausea, irritation of mouth nd throat, sleeping disorder, , muscle spasm, and hypokalemia. There are a number of side effects with terbutaline that you should report immediately to your healthcare provider. These include: • Worsening breathing problems • Irregular heart rhythms (arrhythmias), or feeling of chest pain
WARNINGS MEXATALIN should used with cautionin patients with diabetes mellitus, hyperthyroidism, and a history of heart disease, irregular heart rhythm or angina. Pregnancy & Lactation: terbutaline should be used during pregnancy and lactation only after asking the physician.
DRUG INTERACTIONS The concomitant use of terbutaline with other sympathomimetic agents is not recommended, since the combined effect on the cardiovascular system may be deleterious to the patient. Monoamine Oxidase Inhibitors or Tricyclic Antidepressants: Terbutaline should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, since the action of terbutaline on the vascular system may be potentiated. Beta-Blockers: Beta-adrenergic receptor blocking agents not only block the pulmonary effect of beta-agonists, such as terbutaline, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta-blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents in patients with asthma. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. Diuretics: The ECG changes and/or hypokalemia that may result from the administration of nonpotassium-sparing diuretics can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonists with nonpotassium-sparing diuretics
Pregnancy And lactations terbutaline should be used during pregnancy and lactation only after asking the physician.
Dosage And Administration Adults & Children 12 years and over: 2-3 teaspoonful (10-15 ml) 3 times in 24 hours. Children: 0.075 mg (0.25 ml)/kg body weight 3 times in 24 hr. Under 3 years: ½ teaspoonful. 3-5 years: ½ to 1 teaspoonful. 6-12 years: 1-1½ teaspoonful.
OVERDOSE The expected symptoms with overdosage are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the symptoms listed under side effects, e.g., seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats per minute, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, and insomnia. Hypokalemia may also occur. There is no specific antidote. Treatment consists of discontinuation of terbutaline together with appropriate symptomatic therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of terbutaline.
Storage Conditions Keep below 25° C Keep out of reach of children